By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Morris Corporate Center III
400 Interpace Parkway
Parippany  New Jersey  07054  U.S.A.
Phone: 1-862-261-7000 Fax: n/a


Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.

"Twice As" Video

"Our Winning Way" Video

Key Statistics

Ownership: Public

Web Site: Actavis
Symbol: ACT


Company News
Best Value In Biotech? Actavis (ACT), Says UBS 11/18/2014 12:45:17 PM
Actavis (ACT) Successfully Completes Durata Therapeutics, Inc.  (DRTX) Tender Offer 11/17/2014 11:49:35 AM
Actavis (ACT) Agrees To Buy Allergan Inc. (AGN) For $66 Billion 11/17/2014 8:01:44 AM
Actavis (ACT) Announces FDA Acceptance Of sNDA For SAPHRIS® (asenapine) For The Treatment Of Bipolar I Disorder In Pediatric Patients 11/13/2014 9:16:03 AM
Actavis (ACT) In Talks To Buy Allergan Inc. (AGN) For Over $60 Billion 11/12/2014 1:19:26 PM
Actavis (ACT) Names Maria Teresa Hilado Chief Financial Officer 11/11/2014 8:20:20 AM
Actavis (ACT) Announces Planned Retirement Of R. Todd Joyce In Early 2015 11/5/2014 8:16:55 AM
Actavis (ACT) Net Revenue Increases 83% To $3.7 Billion In Third Quarter 2014; Non-GAAP EPS Increases 53% To $3.19 11/5/2014 8:12:05 AM
Allergan Inc. (AGN) Confirms Second Suitor Wants To Buy It, Is It Actavis (ACT)? 11/4/2014 6:53:11 AM
Actavis (ACT) And Durata Therapeutics, Inc.  (DRTX) Receive U.S. FTC Clearance For Actavis' Proposed Acquisition Of Durata 11/3/2014 7:28:53 AM